Purple Biotech - Asset Resilience Ratio
Purple Biotech (PPBT) has an Asset Resilience Ratio of 6.13% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PPBT current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Purple Biotech's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Purple Biotech assets under control.
Liquid Assets Composition Over Time
This chart breaks down Purple Biotech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Purple Biotech long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $869.00K | 6.13% |
| Total Liquid Assets | $869.00K | 6.13% |
Asset Resilience Insights
- Limited Liquidity: Purple Biotech maintains only 6.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Purple Biotech Industry Peers by Asset Resilience Ratio
Compare Purple Biotech's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Purple Biotech (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Purple Biotech.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.88% | $856.99K | $17.57 Million | +1.85pp |
| 2024-12-31 | 3.03% | $1.12 Million | $37.04 Million | +0.95pp |
| 2023-12-31 | 2.08% | $923.00K | $44.30 Million | -29.19pp |
| 2022-12-31 | 31.27% | $17.08 Million | $54.62 Million | -20.45pp |
| 2021-12-31 | 51.73% | $36.31 Million | $70.20 Million | -3.83pp |
| 2020-12-31 | 55.56% | $46.56 Million | $83.80 Million | +41.90pp |
| 2019-12-31 | 13.66% | $2.01 Million | $14.72 Million | +3.33pp |
| 2018-12-31 | 10.33% | $1.52 Million | $14.72 Million | -14.26pp |
| 2017-12-31 | 24.59% | $3.49 Million | $14.18 Million | -28.37pp |
| 2016-12-31 | 52.96% | $7.90 Million | $14.91 Million | -- |
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more